非小细胞肺癌组织化疗前后表皮生长因子受体基因的突变  

Pre-and post-chemotherapy mutation status of epidermal growth factor receptor gene in non-small cell lung cancer

作　　者：王理扬[1] 黄媚娟[1] 李伦[2] 张瑜[1] 卢铀[1] 

机构地区：[1]四川大学华西医院肿瘤中心,成都610041 [2]四川省肿瘤医院病理科,成都610041

出　　处：《肿瘤》2011年第6期517-521,共5页Tumor

摘　　要：目的:探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)患者化疗前、后肿瘤组织中表皮生长因子受体(epidermal growth factor receptor,EGFR)基因外显子19和21的突变状况。方法:提取31例NSCLC患者化疗前、后肿瘤组织标本中的基因组DNA,采用巢式PCR技术扩增EGFR基因外显子19和21,并进行测序分析。结果:6例患者化疗前、后EGFR基因发生突变,其中4例为19号外显子发生缺失突变,2例为2l号外显子发生替代突变,且化疗前、后的突变状况一致。女性患者突变率(2/3)高于男性(4/28)(P=0.029),非吸烟者的突变率(4/9)高于吸烟者(2/22)(P=0.043)。结论:NSCLC组织EGFR基因外显子19和21突变在化疗前、后无明显改变。Objective：To investigate the pre-and post-chemotherapy mutation status of epidermal growth factor receptor（EGFR） exons 19 and 21 in non-small cell lung cancer（NSCLC）.Methods：DNA in tumor tissue samples from 31 patients with NSCLC was extracted before and after chemotherapy.EGFR exons 19 and 21 were amplified by nested PCR,and the sequence of PCR products was detected.Results：The mutation of EGFR was founded in 6 patients with NSCLC before and after chemotherapy.Deletion mutation of EGFR exon 19 occurred in 4 patients and replacement mutation of EGFR exon 21 occurred in 2 patients.The mutation status of EGFR was consistent before and after chemotherapy.The mutation rate of EGFR was higher in females（2/3） than in males（4/28）（P=0.029）.The mutation rate of EGFR was higher in non-smokers（4/9） than in smokers（2/22）（P=0.043）.Conclusion：There are no changes of EGFR exons 19 and 21 mutations in patients with NSCLC before and after chemotherapy.

关 键 词：癌 非小细胞肺 肿瘤治疗方案 受体 表皮生长因子 突变 

分 类 号：R734.2[医药卫生—肿瘤]